Mercer Global Advisors
CORT icon

Mercer Global Advisors’s Corcept Therapeutics CORT Stock Holding History

Mercer Global Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.94M Buy
102,823
+22,805
+28% +$1.38M 0.01% 611
2026
Q1 		$3.23M Sell
80,018
-21,004
-21% -$785K ﹤0.01% 969
2025
Q4 		$3.52M Sell
101,022
-6,212
-6% -$488K 0.01% 849
2025
Q3 		$8.91M Sell
107,234
-12,758
-11% -$923K 0.01% 491
2025
Q2 		$8.81M Buy
119,992
+14,405
+14% +$1.04M 0.02% 417
2025
Q1 		$12.1M Buy
105,587
+15,884
+18% +$967K 0.03% 318
2024
Q4 		$4.52M Sell
89,703
-71
-0.1% -$3.72K 0.01% 568
2024
Q3 		$4.2M Buy
89,774
+7,973
+10% +$283K 0.01% 544
2024
Q2 		$2.66M Buy
81,801
+10,658
+15% +$292K 0.01% 639
2024
Q1 		$1.79M Sell
71,143
-3,537
-5% -$83.6K 0.01% 753
2023
Q4 		$2.43M Buy
74,680
+7,387
+11% +$203K 0.01% 674
2023
Q3 		$1.83M Buy
67,293
+14,644
+28% +$424K 0.01% 738
2023
Q2 		$1.17M Buy
52,649
+7,459
+17% +$172K ﹤0.01% 893
2023
Q1 		$979K Buy
45,190
+3,326
+8% +$72.9K ﹤0.01% 921
2022
Q4 		$850K Buy
41,864
+799
+2% +$20K ﹤0.01% 982
2022
Q3 		$1.05M Buy
41,065
+3,285
+9% +$87.9K 0.01% 824
2022
Q2 		$898K Buy
37,780
+4,817
+15% +$105K 0.01% 894
2022
Q1 		$742K Buy
32,963
+6,760
+26% +$144K ﹤0.01% 1033
2021
Q4 		$519K Buy
26,203
+2,964
+13% +$60.1K ﹤0.01% 1184
2021
Q3 		$457K Buy
23,239
+1,445
+7% +$30.2K ﹤0.01% 1208
2021
Q2 		$479K Buy
21,794
+1,543
+8% +$34.3K ﹤0.01% 1163
2021
Q1 		$482K Buy
20,251
+2,145
+12% +$57.3K ﹤0.01% 1095
2020
Q4 		$474K Buy
18,106
+2,685
+17% +$56.6K 0.01% 884
2020
Q3 		$268K Buy
15,421
+3,222
+26% +$51.3K ﹤0.01% 1001
2020
Q2 		$205K Buy
+12,199
New +$171K ﹤0.01% 995

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mercer Global Advisors's CORT Position: Q2 2026 in Review

Mercer Global Advisors increased its Corcept Therapeutics (CORT) stake by 28% in Q2 2026, buying an estimated $1.38M and bringing the position to 102,823 shares worth $8.94M. The position accounts for 0.01% of the portfolio, ranked #611.

Mercer Global Advisors first reported a position in CORT in Q2 2020 and has held it in 25 quarters since. The position peaked at $12.1M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Mercer Global Advisors held 102,823 shares of Corcept Therapeutics worth $8.94M as of Q2 2026.
  • Mercer Global Advisors bought 22,805 Corcept Therapeutics shares in Q2 2026, an estimated $1.38M.
  • Corcept Therapeutics made up 0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #611 holding.
  • Mercer Global Advisors first reported a position in Corcept Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Mercer Global Advisors's Corcept Therapeutics position peaked at $12.1M in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.